JMP Securities Reiterates Market Outperform on Aquestive Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities has reiterated its Market Outperform rating for Aquestive Therapeutics, maintaining a price target of $9.

October 08, 2024 | 6:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated its Market Outperform rating for Aquestive Therapeutics, maintaining a price target of $9. This suggests confidence in the company's future performance.
The reiteration of a Market Outperform rating and a maintained price target of $9 by JMP Securities indicates a positive outlook on Aquestive Therapeutics' stock. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100